Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

• February 26, 2025

• Dana-Farber